Incyte(US:INCY)2025-07-29 12:00Financial Performance - Total product revenues reached $1059 million, a 17% year-over-year increase[16] - Total revenues increased by 16% year-over-year, reaching $1216 million[17] - Jakafi net sales were $764 million, representing an 8% year-over-year growth[20] - Opzelura net sales totaled $164 million, a 35% year-over-year increase[29] - Niktimvo net sales reached $36 million in Q2 2025[30] - Other Hematology & Oncology global net sales were $131 million, a 66% year-over-year increase[37] Guidance and Expectations - Full-year 2025 Jakafi revenue guidance raised to $3000 - $3050 million[25] - Full-year 2025 Opzelura revenue guidance set at $630 - $670 million[29] - Full-year 2025 Other Hematology & Oncology revenue guidance raised to $500 - $520 million[38] Research and Development - The company aims to have more than 10 high impact launches by 2030[6, 43] - Initiate registrational trial in ET by early 2026[46] - NDA submission for povorcitinib is expected in early 2026[6, 54]